Value of alpha-foetoprotein for screening of recurrence in hepatocellular carcinoma post resection

Singapore Medical Journal

Volumn 53, Issue 1, 2012, Pages 32-35

  Chang, S K Y ^a   Hlaing, W W ^a   Yu, R Q ^a   Lee, T W V ^a   Ganpathi, I S ^a   Madhavan, K K ^a  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

Alpha foetoprotein; Hepatocellular carcinoma; Recurrence; Screening

Indexed keywords

ALPHA FETOPROTEIN;

ALCOHOL CONSUMPTION; ARTICLE; CANCER RECURRENCE; CANCER SCREENING; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GENDER; HEPATITIS B; HEPATITIS C; HISTOPATHOLOGY; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; RACE; RETROSPECTIVE STUDY; TUMOR VOLUME;

ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; DATABASES, FACTUAL; FEMALE; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MEDICAL ONCOLOGY; MODELS, STATISTICAL; RECURRENCE; RETROSPECTIVE STUDIES; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 84862907454     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94:153-6.
2. Curado MP, Edwards B, Shin HR, et al, eds. Cancer Incidence in Five Continents, Vol IX. Lyon: IARC Scientific Publications No. 160, 2007.
3. Singapore Ministry of Health. Statistics: Health Facts Singapore 2003-2007 [online]. Available at: www.moh.gov.sg /mohcorp/statistics. aspx?id=23712. Accessed March 8, 2011.
4. Bismuth H, Chiche L, Castaing D. Surgical treatment of hepatocellular carcinomas in noncirrhotic liver: experience with 68 liver resections. World J Surg 1995; 19:35-41.
5. Ren FY, Piao XX, Jin AL. Efficacy of ultrasonography and alpha-fetoprotein on early detection of hepatocellular carcinoma. World J Gastroenterol 2006; 12:4656-9.
6. Tateishi R, Yoshida H, Matsuyama Y, et al. Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review. Hepatol Int 2008; 2:17-30.
7. Leone N, Rizzetto M. [Screening for hepatocellular carcinoma]. Minerva Med 2005; 96:95-108. Italian.
8. Durazzo M, Borghesio E, Regge D, Milone PA, Rizzetto M. [A case of hepatocarcinoma preceded by several years by "isolated" increase in alphafetoprotein]. Minerva Gastroenterol Dietol 1992; 38:167-9. Italian.
9. Sherman M. Alphafetoprotein: an obituary. J Hepatol 2001; 34:603-5.
10. Yang B, Zhang B, Xu Y, et al. Prospective study of early detection for primary liver cancer. J Cancer Res Clin Oncol 1997; 123:357-60.
11. Kemmer N, Neff G, Kaiser T, et al. An analysis of the UNOS liver transplant registry: high serum alpha-fetoprotein does not justify an increase in MELD points for suspected hepatocellular carcinoma. Liver Transpl 2006; 12:1519-22.
12. Cottone M, Turri M, Caltagirone M, et al. Screening for hepatocellular carcinoma in patients with Child's A cirrhosis: an 8-year prospective study by ultrasound and alphafetoprotein. J Hepatol 1994; 21:1029-34.
13. Shirabe K, Takenaka K, Gion T, et al. Significance of alpha-fetoprotein levels for detection of early recurrence of hepatocellular carcinoma after hepatic resection. J Surg Oncol 1997; 64:143-6.
14. Soresi M, Magliarisi C, Campagna P, et al. Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. Anticancer Res 2003; 23:1747-53.
15. Sherman M. The resurrection of alphafetoprotein. J Hepatol 2010; 52:939-40.
16. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130:417-22.
17. NCCN Clinical Practice Guidelines in Oncology, Hepatobiliary cancers, Version 1.2011 [online]. Available at www.nccn.org/professionals/ physician_gls/f_guidelines.asp. Accessed March 8, 2011.